Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription 16.09.2024 1 Aliment Pharmacol Ther 1 BMC Gastroenterol 1 Clin Exp Immunol 4 Dig Dis Sci 3 Dis Colon Rectum 1 Eur J Gastroenterol Hepatol 2 Gastroenterology 2 Gut 3 Inflamm Bowel Dis 3 J Crohns Colitis 1 J Gastroenterol 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. GRANOT M, Kopylov U, Loberman-Nachum N, Krauthammer A, et al
   Differences in disease characteristics and treatment exposures between paediatric and adult-onset inflammatory bowel disease using a registry-based cohort.
   Aliment Pharmacol Ther. 2024 Sep 10. doi: 10.1111/apt.18264.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

2. NA JE, Park YE, Park J, Kim TO, et al
   Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naive and bio-experienced Crohn's disease patients: a retrospective multicenter study.
   BMC Gastroenterol. 2024;24:306.
   PubMed         Abstract available
   
   

   
   Clin Exp Immunol

3. HUI L, Huang MK, Dai QK, Miao CL, et al
   Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease.
   Clin Exp Immunol. 2024 Sep 9:uxae082. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

4. NEWLAND JJ, Sundel MH, Blackburn KW, Vessilenov R, et al
   Association of Race and Postoperative Outcomes in Patients with Inflammatory Bowel Disease.
   Dig Dis Sci. 2024 Sep 11. doi: 10.1007/s10620-024-08594.
   PubMed         Abstract available
   
   
5. ODAH T, Karime C, Desai A, Picco MF, et al
   Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib.
   Dig Dis Sci. 2024 Sep 9. doi: 10.1007/s10620-024-08630.
   PubMed         Abstract available
   
   
6. ESCHER JC
   Transition or Transfer Readiness in Young Patients with IBD: What Does It Really Mean? : Invited commentary on Khan SM et al, A Smooth Transition: Assessing Transition Readiness In Adolescents with Inflammatory Bowel Disease (2024).
   Dig Dis Sci. 2024 Sep 9. doi: 10.1007/s10620-024-08624.
   PubMed        
   
   
7. CLARKE LM, Riascos MC, Redston MS, Hamilton MJ, et al
   Ileal Signet Ring Adenocarcinoma in Crohn's Disease: Unanticipated Diagnosis After Surgical Resection of a Symptomatic Stricture.
   Dig Dis Sci. 2024 Sep 9. doi: 10.1007/s10620-024-08621.
   PubMed        
   
   

   
   Dis Colon Rectum

8. LIGHTNER AL
   Rethinking the Pathophysiology of Ulcerative Colitis: Beyond the Mucosa.
   Dis Colon Rectum. 2024 Sep 10. doi: 10.1097/DCR.0000000000003535.
   PubMed        
   
   
9. ZHU F, Dong T, Tang C, Wei J, et al
   A Mesenteric Fat-Derived Radiomic Model to Identify Colonic Fibrosis and Predict Treatment Response to Biologics in Chronic Ulcerative Colitis.
   Dis Colon Rectum. 2024 Sep 10. doi: 10.1097/DCR.0000000000003468.
   PubMed         Abstract available
   
   
10. HADIZADEH A, Akbari-Asbagh R, Heirani-Tabasi A, Soleimani M, et al
    Localized Administration of Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Refractory Perianal Fistula in Crohn's Disease Patients: A Phase II Clinical Trial.
    Dis Colon Rectum. 2024 Sep 6. doi: 10.1097/DCR.0000000000003502.
    PubMed         Abstract available
    
    

    
    Eur J Gastroenterol Hepatol

11. DU J, Xu F, Qiu X, Hu X, et al
    A novel computed tomography enterography radiomics combining intestinal and creeping fat features could predict surgery risk in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2024 Aug 23. doi: 10.1097/MEG.0000000000002839.
    PubMed         Abstract available
    
    

    
    Gastroenterology

12. ROSHANOV PS, Khanna R
    A Head-to Head Comparison of Risankizumab and Ustekinumab as second line therapy in moderate to severely active Crohn's disease.
    Gastroenterology. 2024 Sep 7:S0016-5085(24)05445.
    PubMed        
    
    
13. ROSHANOV PS, Khanna R
    Risankizumab for Induction and Maintenance of Remission in Ulcerative Colitis.
    Gastroenterology. 2024 Sep 7:S0016-5085(24)05444.
    PubMed        
    
    

    
    Gut

14. ERKERT L, Gamez-Belmonte R, Kabisch M, Schodel L, et al
    Alzheimer's disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis.
    Gut. 2024;73:1618-1631.
    PubMed         Abstract available
    
    
15. CARPAY N, de Boer NKH, Neefjes-Borst A, Bots S, et al
    Severe multiple therapy refractory colitis in a 46-year-old man.
    Gut. 2024;73:1617-1736.
    PubMed        
    
    

    
    Inflamm Bowel Dis

16. AZIZ S, Akhlaq A, Owings A, Gurz S, et al
    Mortality Trends in Inflammatory Bowel Disease by Age, Sex, and Race in the United States from 1999 to 2020.
    Inflamm Bowel Dis. 2024 Sep 11:izae184. doi: 10.1093.
    PubMed         Abstract available
    
    
17. KELUTH CHAVAN A, Jha P, Perez JA, Harper E, et al
    Risk of Paradoxical Rheumatoid Arthritis in Inflammatory Bowel Disease Patients Exposed to Tumor Necrosis Factor Inhibitors: A Propensity-Matched Multicenter Study.
    Inflamm Bowel Dis. 2024 Sep 11:izae203. doi: 10.1093.
    PubMed        
    
    
18. GUO A, Ludvigsson J, Lerchova T, Imberg H, et al
    Association Between Maternal Infections in Pregnancy and the Risk of Inflammatory Bowel Disease in the Offspring: Findings From Two Scandinavian Birth Cohorts.
    Inflamm Bowel Dis. 2024 Sep 9:izae209. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

19. CUI Y, David M, Bouchareychas L, Rouquier S, et al
    IL23R-specific CAR Tregs for the treatment of Crohn's disease.
    J Crohns Colitis. 2024 Sep 10:jjae135. doi: 10.1093.
    PubMed         Abstract available
    
    
20. DUAN S, Chen P, Liang C, Zhang Y, et al
    Comparative Efficacy of Novel Biologics, Antitumour Necrosis Factor Agents, and Immunomodulators to Prevent Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-analysis.
    J Crohns Colitis. 2024 Sep 9:jjae143. doi: 10.1093.
    PubMed         Abstract available
    
    
21. AL SULAIS E, Louis E, Bokemeyer B, Gecse KB, et al
    Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire.
    J Crohns Colitis. 2024 Sep 7:jjae138. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

22. CHEN G, Wu X, Zhu H, Li K, et al
    Multisample lipidomic profiles of irritable bowel syndrome and irritable bowel syndrome-like symptoms in patients with inflammatory bowel disease: new insight into the recognition of the same symptoms in different diseases.
    J Gastroenterol. 2024 Sep 10. doi: 10.1007/s00535-024-02148.
    PubMed         Abstract available
    
    

    
    PLoS One

23. PUSA T, Rousu J
    Stable biomarker discovery in multi-omics data via canonical correlation analysis.
    PLoS One. 2024;19:e0309921.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.